RxDoctor Payments Data

Nicholas Pleat, DO

Hematology & Oncology · Fairfield, OHNPI 1609163260

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 63 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$166
  • Daiichi Sankyo Inc.$142
  • E.r. Squibb & Sons, L.L.C.$111
  • Incyte Corporation$97
  • AstraZeneca$91
  • Astellas Pharma US Inc$84
  • plus $499 from 17 others

What the payments were for

  • Food & beverage$98282%
  • Education$20918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$49,559
Medicare patients
173
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib45$710,768
Lenalidomide26$384,128
CalquenceAcalabrutinib Maleate12$326,197
Abiraterone Acetate168$289,712
IbrancePalbociclib19$282,345
XtandiEnzalutamide16$224,883
SprycelDasatinib12$215,188
BosulifBosutinib12$57,571
Imatinib Mesylate12$41,575
EliquisApixaban39$37,062
XareltoRivaroxaban15$13,661
Anastrozole278$4,562
Hydroxyurea94$1,859
Dexamethasone33$1,627
Letrozole57$1,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$12$710,76845 claims
PfizerIbrance, Bosulif, Eliquis$34$376,97770 claims
AstraZenecaCalquence$91$326,19712 claims
Astellas Pharma US IncXtandi$84$224,88316 claims
E.r. Squibb & Sons, L.L.C.Sprycel$111$215,18812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Fairfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →